AMAG Pharmaceuticals Inc (AMAG.O)

AMAG.O on Nasdaq

36.80USD
25 Nov 2014
Price Change (% chg)

$0.31 (+0.85%)
Prev Close
$36.49
Open
$36.75
Day's High
$37.08
Day's Low
$36.24
Volume
372,583
Avg. Vol
528,946
52-wk High
$37.08
52-wk Low
$16.49

AMAG.O

Chart for AMAG.O

About

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company markets Feraheme, an iron compound for the treatment of iron deficiency anemia in adult patients, and MuGard Mucoadhesive Oral Wound Rinse, an oral rinse for treating oral mucositis. Feraheme (ferumoxytol) Injection is indicated for the treatment of... (more)

Overall

Beta: 0.06
Market Cap (Mil.): $806.24
Shares Outstanding (Mil.): 22.09
Dividend: --
Yield (%): --

Financials

  AMAG.O Industry Sector
P/E (TTM): -- 38.28 39.18
EPS (TTM): -0.50 -- --
ROI: -3.36 17.89 17.24
ROE: -5.84 18.63 18.11
Search Stocks

Amag Pharma enters women health business with $675 million deal

- Amag Pharmaceuticals Inc entered the women's healthcare business by acquiring privately held Lumara Health Inc for $675 million in its biggest deal ever, sending its shares up as much as 23 percent to a four-year high.

29 Sep 2014

UPDATE 2-Amag Pharma enters women health business with $675 mln deal

(Adds CEO and analyst comments, background, updates stock price)

29 Sep 2014

BUZZ-U.S. Stocks on the Move-Ambit, Athlon, Tonix, Tibco, Amag

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

29 Sep 2014

Deals of the day- Mergers and acquisitions

(Adds Encana Corp, Nestle, Tibco Software, Amag Pharmaceuticals; Updates Strides Arcolab and Barco)

29 Sep 2014

Amag Pharma buys women's health company Lumara for $675 mln

Sept 29 - Amag Pharmaceuticals Inc said it would buy privately held women's healthcare company Lumara Health Inc for $675 million in cash and stock, gaining access to the only approved product designed to reduce the risk of preterm birth.

29 Sep 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks